Advances in Treatment and Management of Immune Thrombocytopenia

Opening their discussion on immune thrombocytopenia (ITP), expert panelists review criteria for diagnosis and highlight differences between adult and pediatric populations.

Shared insight on treatment goals for immune thrombocytopenia and how physicians might optimally select frontline therapy.

A commentary on the significance of the patient’s age in treating and managing ITP.

Expert perspectives on how to identify chronic or persistent disease in patients diagnosed with immune thrombocytopenia.

Panelists consider when they would select splenectomy over second-line systemic therapy in patients with immune thrombocytopenia.

Focusing on second-line systemic agents in immune thrombocytopenia, experts review the historical use of rituximab therapy.

Expert perspectives on the selection and use of fostamatinib as second-line therapy in patients with immune thrombocytopenia.

Shared insight on thrombopoietin receptor agonist (TPO-RA) use in the pediatric setting of immune thrombocytopenia management.

A brief discussion of factors that influence selection of oral versus injectable TPO-RA therapy for ITP.

Expert panelists consider clinical trial data on and personal experience with using eltrombopag, an oral TPO-RA, in immune thrombocytopenia.

A commentary on clinical experience with avatrombopag, another oral TPO-RA, in treating ITP.

Considerations for the uptake and use of romiplostim, an injectable thrombopoietin receptor agonist, in immune thrombocytopenia.

Comprehensive discussion on nuancing the risk of thrombosis with thrombopoietin receptor agonists in immune thrombocytopenia.

Experts consider how treatment duration can impact patient outcomes in immune thrombocytopenia and discuss discontinuation of TPO-Ras.

A brief review of how the management of patients with immune thrombocytopenia has been impacted by the COVID-19 pandemic.

Shared insight on clinical trials investigating the frontline use of thrombopoietin receptor agonists in patients with immune thrombocytopenia.

Panelists review data behind sutimlimab, a complement inhibitor being investigated in the setting of immune thrombocytopenia.

Before closing out their discussion on novel treatment approaches in ITP, experts review data behind FcR-, BTK-, and CD38-targeted therapies.

Expert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.